Do Drugs Given Expedited Approval Have More Safety Risks? GAO Says US FDA Can't Tell

The US Government Accountability Office (GAO) gave the Food and Drug Administration a negative report card on its post-market oversight of drugs approved with a fast track or breakthrough therapy designation, finding the agency's data on safety issues for these drugs is unreliable and difficult to access.